Open AccessGuideline Concordance with Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience
Author(s) -
Nabiel Mir
Publication year - 2020
Publication title -
federal practitioner
Language(s) - English
Resource type - Journals
pISSN - 1078-4497
DOI - 10.12788/fp.0056
Subject(s) - durvalumab , veterans affairs , medicine , lung cancer , stage (stratigraphy) , cancer , adverse effect , retrospective cohort study , nivolumab , paleontology , immunotherapy , biology
Durvalumab is recommended by national guidelines for patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy (CRT). Nonadherence to guidelines is associated with adverse outcomes. We studied the adherence and identified barriers to durvalumab usage at the Birmingham Veterans Affairs Medical Center (VAMC) Oncology Clinic in Alabama.